Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Feb 24, 2022 (5 years ago)

hydrALAZINE HCl Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Impurities/Degradation Specifications: Out of specification result obtained during routine stability testing for Impurities.

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

hydrALAZINE HCl Tablets, USP, 10 mg, 100 Tablets per carton (10x10 blister packs), Rx only, Distributed by: MAJOR PHARMACEUTICALS, Livonia, MI 48152 USA. NDC # 0904-6440-61

Affected NDC 0904-6440-61

Compare with the code on your package — it is the most precise check available.

Drug: Hydralazine

Recalling firm
The Harvard Drug Group
NDC code
0904-6440-61
Origin
MI, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0653-2022 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Hydralazine recalls

See all
Class III · Low risk

Hydralazine HCl Tablets

Failed Impurities/Degradation Specifications; during routine stability testing for impurities.

Terminated Impurity / degradation The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories NDC 0904-6441-61 D-0045-2025
Class II · Moderate risk

HydrALAZINE Hydrochloride Tablets

an out of specification result obtained during routine stability testing for Impurities. There is a remote possibility that use of this product could cause a medically reversible or transient adverse health consequences.

Terminated Impurity / degradation The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories NDC 0904-6440-61 D-0324-2024
Class III · Low risk

HydrALAZINE Hydrochloride Tablets

Failed Impurities/Degradation Specifications: Out of Specification (OOS) result in the repackaged product for Related Compounds (Impurities) at the 6-month time point.

Terminated Impurity / degradation Amerisource Health Services LLC D-0320-2024

Other recalls by The Harvard Drug Group

All 2022 recalls
Class II · Moderate risk

Omega-3-Acid

Failed Capsule Specifications: Out of specification results obtained during routine stability testing for Loss on Drying of Capsule Shells.

Ongoing Failed specification The Harvard Drug Group LLC D-0493-2026